Team Gleason teams with Synchron to raise BCI Community awareness
Team Gleason has expanded its collaboration with Synchron to raise awareness about the company’s BCI Community, an initiative…
Articles by Esteban Dominguez Cerezo, MS
Number of US ALS cases expected to increase 10% this decade: Study
The number of people living with amyotrophic lateral sclerosis (ALS) in the U.S. is expected to steadily climb —…
Muscle mass biomarker is associated with risk of developing ALS: Study
A muscle mass biomarker called the creatinine-to-cystatin C ratio (CCR) may indicate the risk of developing amyotrophic lateral sclerosis…
First ALS patient dosed in Phase 1 trial testing Quralis’ QRL-101
Quralis has dosed the first patient in a Phase 1 clinical trial testing QRL-101 — its treatment candidate for…
Treatment for improving gut microbiome found safe in ALS
MaaT033, an experimental oral therapy for improving the gut microbiome — the collection of microbes, including bacteria, in the human…
Neuralink’s brain-computer interface trial recruiting in Canada
The University Health Network (UHN) in Toronto was selected as the first site in Canada to be part of a…
Phase 1 trial now testing 2 new QRL-201 doses in ALS patients
A Phase 1 clinical trial of QRL-201, Quralis‘ therapy candidate for amyotrophic lateral sclerosis (ALS), has successfully completed…
Ontario commits CA$13 million to address ALS community needs
The government of Ontario has committed CA$13 million (around $9.36 million) over three years to provide critical and comprehensive care…
Leal raises $45M to advance LTX-002 to clinical trials for ALS
Leal Therapeutics has raised $45 million to continue advancing its pipeline of drugs for diseases of the brain and spinal…
Auttx gets ALS Network grant to develop new treatments for ALS
Biotech company Auttx has received a $125,000 grant to advance the development of new molecules that aim to restore normal…